Home > Insider Trading > Filing (0001181431-13-041163)

Filing Details

Accession Number:: 0001181431-13-041163
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2013-07-23 19:11:38
Reporting Period:: 2013-07-23

Filing Date:: 2013-07-23
Accepted Time:: 2013-07-23 19:11:38
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1302573	Oncomed Pharmaceuticals Inc	OMED	Pharmaceutical Preparations (2834)	383572512

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1165583	Lvp Life Science Ventures I, L.p.	One Embarcadero Center Suite 4050 San Francisco CA 94111	No	No	Yes	No
1201886	F Patrick Latterell	One Embarcadero Center Suite 4050 San Francisco CA 94111	No	No	Yes	No
1332654	L.p. Iii Ventures Science Life Lvp	One Embarcadero Center Suite 4050 San Francisco CA 94111	No	No	Yes	No
1341508	Lvp Iii Associates, L.p.	One Embarcadero Center Suite 4050 San Francisco CA 94111	No	No	Yes	No
1384607	Lvp Gp I, Llc	One Embarcadero Center Suite 4050 San Francisco CA 94111	No	No	Yes	No
1384614	Lvp Gp Ii, Llc	One Embarcadero Center Suite 4050 San Francisco CA 94111	No	No	Yes	No
1384617	Lvp Life Science Ventures Ii, L.p.	One Embarcadero Center Suite 4050 San Francisco CA 94111	No	No	Yes	No
1384618	Lvp Iii Partners Lp	One Embarcadero Center Suite 4050 San Francisco CA 94111	No	No	Yes	No
1581469	Lvp Gp Iii, Llc	One Embarcadero Center Suite 4050 San Francisco CA 94111	No	No	Yes	No
1581471	Lvpmc, Llc	One Embarcadero Center Suite 4050 San Francisco CA 94111	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2013-07-23	100,000	$0.00	100,000	No	4	C	Indirect	Directly owned by LVP I
Common Stock	Acquisiton	2013-07-23	65,476	$0.00	165,476	No	4	C	Indirect	Directly owned by LVP I
Common Stock	Acquisiton	2013-07-23	74,142	$0.00	239,618	No	4	C	Indirect	Directly owned by LVP I
Common Stock	Acquisiton	2013-07-23	7,937	$17.00	247,555	No	4	P	Indirect	Directly owned by LVP I
Common Stock	Acquisiton	2013-07-23	426,315	$0.00	426,315	No	4	C	Indirect	Directly owned by LVP II
Common Stock	Acquisiton	2013-07-23	279,135	$0.00	705,450	No	4	C	Indirect	Directly owned by LVP II
Common Stock	Acquisiton	2013-07-23	316,079	$0.00	1,021,529	No	4	C	Indirect	Directly owned by LVP II
Common Stock	Acquisiton	2013-07-23	33,834	$17.00	1,055,363	No	4	P	Indirect	Directly owned by LVP II
Common Stock	Acquisiton	2013-07-23	611,995	$0.00	611,995	No	4	C	Indirect	Directly owned by LVP III
Common Stock	Acquisiton	2013-07-23	692,994	$0.00	1,304,989	No	4	C	Indirect	Directly owned by LVP III
Common Stock	Acquisiton	2013-07-23	43,223	$17.00	1,348,212	No	4	P	Indirect	Directly owned by LVP III
Common Stock	Acquisiton	2013-07-23	30,599	$0.00	30,599	No	4	C	Indirect	Directly owned by Associates
Common Stock	Acquisiton	2013-07-23	34,649	$0.00	65,248	No	4	C	Indirect	Directly owned by Associates
Common Stock	Acquisiton	2013-07-23	2,161	$17.00	67,409	No	4	P	Indirect	Directly owned by Associates
Common Stock	Acquisiton	2013-07-23	15,299	$0.00	15,299	No	4	C	Indirect	Directly owned by Partners
Common Stock	Acquisiton	2013-07-23	17,324	$0.00	32,623	No	4	C	Indirect	Directly owned by Partners
Common Stock	Acquisiton	2013-07-23	1,080	$17.00	33,703	No	4	P	Indirect	Directly owned by Partners

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	Directly owned by LVP I
No	4	C	Indirect	Directly owned by LVP I
No	4	C	Indirect	Directly owned by LVP I
No	4	P	Indirect	Directly owned by LVP I
No	4	C	Indirect	Directly owned by LVP II
No	4	C	Indirect	Directly owned by LVP II
No	4	C	Indirect	Directly owned by LVP II
No	4	P	Indirect	Directly owned by LVP II
No	4	C	Indirect	Directly owned by LVP III
No	4	C	Indirect	Directly owned by LVP III
No	4	P	Indirect	Directly owned by LVP III
No	4	C	Indirect	Directly owned by Associates
No	4	C	Indirect	Directly owned by Associates
No	4	P	Indirect	Directly owned by Associates
No	4	C	Indirect	Directly owned by Partners
No	4	C	Indirect	Directly owned by Partners
No	4	P	Indirect	Directly owned by Partners

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2013-07-23	100,000	$0.00	100,000	$0.00
Common Stock	Series A Preferred Stock	Disposition	2013-07-23	426,315	$0.00	426,315	$0.00
Common Stock	Series B Preferred Stock	Disposition	2013-07-23	65,476	$0.00	65,476	$0.00
Common Stock	Series B Preferred Stock	Disposition	2013-07-23	279,135	$0.00	279,135	$0.00
Common Stock	Series B Preferred Stock	Disposition	2013-07-23	611,995	$0.00	611,995	$0.00
Common Stock	Series B Preferred Stock	Disposition	2013-07-23	30,599	$0.00	30,599	$0.00
Common Stock	Series B Preferred Stock	Disposition	2013-07-23	15,299	$0.00	15,299	$0.00
Common Stock	Series B-1 Preferred Stock	Disposition	2013-07-23	74,142	$0.00	74,142	$0.00
Common Stock	Series B-1 Preferred Stock	Disposition	2013-07-23	316,079	$0.00	316,079	$0.00
Common Stock	Series B-1 Preferred Stock	Disposition	2013-07-23	692,994	$0.00	692,994	$0.00
Common Stock	Series B-1 Preferred Stock	Disposition	2013-07-23	34,649	$0.00	34,649	$0.00
Common Stock	Series B-1 Preferred Stock	Disposition	2013-07-23	17,324	$0.00	17,324	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	43,859	Indirect	Directly owned by LVPMC

Footnotes

Each share of Series A, Series B and Series B-1 Preferred Stock automatically converted on a one-to-one basis into Common Stock immediately prior to the consummation of the Issuer's initial public offering on July 23, 2013.
The reported securities are owned directly by each of LVPMC, LLC ("LVPMC"), LVP Life Science Ventures I, L.P. ("LVP I"), LVP Life Science Ventures II, L.P. ("LVP II"), LVP Life Science Ventures III, L.P ("LVP III"), LVP III Associates, L.P. ("Associates") and LVP III Partners, L.P. ("Partners"). LVP GP I, LLC ("GP I") is the general partner of LVP I, LVP GP II, LLC ("GP II") is the general partner of LVP II and LVP GP III, LLC ("GP III") is the general partner of LVP III, Associates and Partners. (Continued on Footnote 3)
GP I, GP II and GP III may be deemed to have sole voting power and dispositive power over the shares held by LVP I, LVP II, LVP III, Associates and Partners. Each of GP I, GP II, GP III and Patrick Latterell, the managing member of each of GP I, GP II and GP III and the manager of LVPMC may be deemed to share voting and dispositive power over the reported securities and disclaim beneficial ownership of the reported securities held by LVPMC, LVP I, LVP II, LVP III, Associates and Partners except to the extent of any pecuniary interest therein. James W. Woody, M.D., Ph.D., as a member of each of GP I, GP II and GP III, may be deemed to share voting and dispositive power over the reported securities held by LVP I, LVP II, LVP III, Associates and Partners, and disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein.
The securities are immediately convertible.
The expiration date is not relevant to the conversion of these securities.